At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure (defined as worsening heart failure symptoms in addition to hospitalization or the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

SUMMIT was the first trial in patients with heart failure with preserved ejection fraction (HFpEF ... like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on ...

The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and ...

Heart failure with preserved ejection fraction, or HFpEF, occurs when the heart pumps normally but is too stiff to fill properly. Current research suggests that HFpEF occurs when chronic medical ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown ... The SUMMIT trial enrolled obese patients with heart failure with preserved ejection fraction (HFpEF) – a particularly hard ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...